Shares of Genus plc (LON:GNS - Get Free Report) reached a new 52-week high during trading on Thursday . The stock traded as high as GBX 3,228.80 ($43.56) and last traded at GBX 2,745 ($37.03), with a volume of 1185687 shares changing hands. The stock had previously closed at GBX 2,500 ($33.72).
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Genus from GBX 2,250 to GBX 2,550 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Shore Capital reiterated a "buy" rating and issued a GBX 2,900 price target on shares of Genus in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Genus currently has a consensus rating of "Buy" and a consensus price target of GBX 2,725.
Check Out Our Latest Analysis on GNS
Genus Trading Down 0.6%
The company has a market capitalization of £1.75 billion, a P/E ratio of -43,064.52, a PEG ratio of 2.87 and a beta of 0.37. The business has a fifty day moving average of GBX 2,451.67 and a 200-day moving average of GBX 2,086.52. The company has a debt-to-equity ratio of 53.12, a quick ratio of 1.08 and a current ratio of 1.80.
Genus (LON:GNS - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The company reported GBX 81.80 earnings per share for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. Analysts anticipate that Genus plc will post 70.9644323 earnings per share for the current fiscal year.
About Genus
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Read More
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.